Wegovy obesity drug by Novo Nordisk lowers risk of attacks
Danish pharmaceutical giant Novo Nordisk has unveiled promising outcomes from a recent trial involving its obesity drug, Wegovy. The study’s findings unveiled that Wegovy yielded an impressive 20% decrease in the risk of heart attacks and strokes among overweight or obese individuals with a history of heart disease. This groundbreaking revelation has surpassed expectations and … Read more